Solid Tumour Section

Uterus: Leiomyoma

Allison M Lynch, Cynthia C Morton

Brigham and Women's Hospital, Harvard New Research Building, 77 Avenue Louis Pasteur, Room 160, Boston, MA 02115, USA

Published in Atlas Database: Update -May 2007
Online updated version: http://AtlasGeneticsOncology.org/Tumors/leiomyomID5031.html
DOI: 10.4267/2042/38483


This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence.
© 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: Uterine fibroids; Uterine fibromyoma; fibroids; fibroma; fibroleiomyoma; myoma
Note: Uterine Leiomyomata (UL), benign smooth muscle tumors of the uterus, are the most common pelvic tumors in women. UL are symptomatic in approximately 25% of reproductive age females and are the primary indicator for hysterectomy in the United States accounting for over 200,000 procedures annually. Careful pathologic examination of the uterus shows over 75% of reproductive age females have UL with the average affected uterus containing six to seven fibroids. UL are frequent in women older than 30 years of age, very rare in woman below the age of 18, and tend to regress after menopause. Rarely are UL estimated to become malignant leiomyosarcoma. They are steroid-hormone dependent tumors and especially sensitive to estrogen and progesterone actively impacting their overall growth and development. See WebPath leiomyoma, leiomyomata, and degeneration.

Classification

Note: Classification of leiomyomas is based on location within the uterus (see figures below).
Uterine Layer
- Subserous: located just beneath the serosal surface. They grow out toward the peritoneal cavity, and can be sessile (broad-based) or pedunculated (attached to the surface by a narrow stalk). The pedunculated ones may attach themselves to adjacent structures like the bowel, omentum or mesentery, and develop a secondary blood supply, loosing its primary uterine blood supply (parasitic leiomyoma). Subserous leiomyomas may also extend into the broad ligament (intraligamentary leiomyomas).
- Intramural: are the most common type of UL, found primarily within the thick myometrium.
- Submucous: are the most symptomatic form of UL, located beneath the endometrium (uterine mucosa). Like subserosal UL, they may be sessile or pedunculated. The pedunculated nodules may protrude through the cervical os, and may undergo torsion, infarction, and separation from the uterus. Submucous leiomyoma are often associated with an abnormality of the endometrium, resulting in a disturbed bleeding pattern.

Clinics and pathology

Epidemiology
Ethnic predisposition studies show leiomyomas are more frequent (from three to nine fold) in women of African origin than women of other ethnic groups. African American women are reported to have an earlier age of UL diagnosis, larger and more abundant tumors, greater symptom severity and higher rates of hysterectomy. Risk factors for UL include early age of menarche, nulliparity, oral contraceptive use and obesity.

Clinics
Clinical presentation depends upon size, location and number of lesions. UL may occur singly but often are multiple, with variations in size. They may manifest with profuse menstrual bleeding, pelvic pain and pressure, and reproductive dysfunction causing significant medical and social morbidity. UL may be a cause of pregnancy complications, such as abortion, hemorrhagic degeneration, disseminated intravascular
coagulation, hemoperitoneum, premature rupture of membranes, dystocia, inversion of the uterus, antepartum and postpartum hemorrhage, breech presentation, placental abruption and postpartum sepsis. They are steroid-hormone dependent and have high estrogen concentrations, elevated numbers of estrogen receptors and more bound estrogen. UL increase in size when exposed to high estrogen levels, such as during the reproductive years and diminish in the presence of low estrogen levels, following menopause or during GnRH agonist therapy. Having more progesterone receptors than normal myometrium, UL also grow in the presence of high progesterone concentrations. Growth hormone (GH) and prolactin (PRL) are thought to promote UL growth, but require further investigation.

**Pathology**

Leiomyomas are dense, well-circumscribed nodules consisting of myometrial-derived smooth muscle cells and extracellular matrix (e.g. collagen, fibronectin, proteoglycan). The cut surfaces are white to tan in color, with a whorled trabecular pattern. The appearance is often altered by degenerative changes. Microscopically, they consist of whorled, anastomosing fascicles of uniform, spindle-shaped, smooth muscle cells. Cells have indistinct borders and abundant fibrillar, eosinophilic cytoplasm. The nuclei are elongated and have finely dispersed chromatin. They may show areas of hemorrhage, as well as cystic degeneration and microcalcification in a minority of lesions.

Despite the variety in the histologic subtypes of leiomyomas, all are grossly similar. In addition to histologically typical UL, several other specific subtypes are distinguished, some of which are very rare:

- **Cellular leiomyoma** (composed of densely cellular fascicles of smooth muscle with little intervening collagen).
- Atypical leiomyoma (containing atypical cells, clustered or distributed through the lesion).
- Epithelioid leiomyoma (composed of round or polygonal cells rather than spindle-shaped. This subtype includes leiomyoblastoma, clear cell leiomyoma, plexiform leiomyoma).
- Myxoid leiomyoma (containing abundant amorphous myxoid substance between the smooth muscle cells).
- Vascular leiomyoma (containing dense proliferations of large, caliber, thick-walled vessels).
- Lipoleiomyoma (consisting of a mixture of mature adipocytes and smooth muscle cells).
- Leiomyoma with tubules (containing tubular structures).
- Benign metastasizing leiomyoma (occurrence of multiple smooth-muscle nodules, most often located in the lung after previous hysterectomy).

Microscopic pathology: see WebPath leiomyoma

### Treatment

Only UL that are symptomatic, enlarge rapidly, or pose diagnostic problems, are typically removed. The traditional and most definitive treatment for UL is hysterectomy (surgical removal of the uterus). Myomectomy is another surgical option for women with fewer and smaller tumors wanting to remove UL, yet maintain fertility. Uterine Artery Embolization (UAE) is a radiological alternative especially effective at treating intramural UL that are difficult to access surgically, yet impact on pregnancy and future fertility is unclear. Despite being expensive and having limited availability, a noninvasive thermoablative procedure known as MRI-guided focused ultrasound (MRgFUS) has recently been shown to target specific UL effectively and decrease recovery time. Certain medications, such as gonadotropin releasing hormone agonists (GnRHs), can alleviate UL symptoms by decreasing estrogen levels to a menopausal-like state. However, current medical therapies cannot prevent recurrence.

### Genetics

**Note:** Familial aggregation and twin studies support the heritability of these tumors. First-degree relatives of women with UL are 2.5 times more likely to develop these tumors than women with unaffected relatives, suggesting a possible predisposition. Glucose-6-phosphate dehydrogenase isoenzyme and androgen receptor polymorphism studies have demonstrated that UL develop as independent clonal lesions. Accordingly, UL may be found with different chromosomal aberrations in the same uterus.

---

### Cytogenetics

**Note:** Approximately 40% of cytogenetically investigated cases show abnormal karyotypes, usually with single or few changes. Rarely, they may show complex karyotypes. The cytogenetic heterogeneity of UL can be attributed to various clonal chromosomal changes such as translocations, deletions and trisomies. Subgroups of common cytogenetic rearrangements include a translocation between chromosomes 12 and 14, trisomy 12, deletions of portions of the long arms of chromosomes 3 or 7 and the short arm of chromosome 1, rearrangements of the short arm of chromosome 6 and rearrangements of chromosomes 1, 3, 10, 13 and X. Although the initiating event for tumorigenesis remains unknown, the variety of cytogenetic abnormalities displayed in UL suggests multiple genetic pathways may be involved.

Correlations between cytogenetics and clinical phenotype:

- Myoma location/incidence of abnormal karyotype:
  - intramural - 35%;
  - subserosal - 29%;
  - submucosal - 12%.
- Type of chromosome abnormality/ tumor mean size:
  - tumors with normal karyotype - 5.4 cm;
  - tumors with del(7q) - 5cm;
  - tumors with t(12; 14) rearrangements - 8.5 cm.

### Cytogenetics morphological t(12;14)(q14-15;q22-24) subgroup.

It is found in approximately 20% of the abnormal cases. The t(12;14)(q14-15;q22-24) translocation is the first chromosome alteration reported in uterine leiomyoma. It may be observed as the sole cytogenetic abnormality, or together with other clonal changes, such as del(7q). The chromosome segment 12q14-15 may be rearranged with other translocation partners (such as chromosomes X, 2, 8, 9, 10, 22) or may undergo pericentric inversion. Myoma cells with this abnormality are responsive to the immortalization by the ‘early region’ of the SV40 genome.

#### t(12;14)(q14-15; q22-24) subgroup - molecular findings:

In this subgroup dysregulation of the HMG2 (formerly HMGIC) gene located at 12q15 has been observed. Chromosome 12 breakpoint is often located 10 kb up to 100 kb 5’ to HMG2, and in a majority of cases there is no fusion transcript. However, in a number of cases the gene is altered:

- case with pericentric inversion: HMG2 exon 3 is fused to ALDH2 exon 13 (12q24.2).
- case with apparently normal karyotype: HMG2 exon 3 is fused to retrotransposon-like sequences RTVLH 3’ LTRs.
case with complex karyotype including chromosome 12 and 14 rearrangements: cumulative dosage effect of a RAD51L1/HMGA2 fusion and RAD51L1 loss.

- case without cytogenetic analysis: HMGA2 exon 3 is fused to COX6C exon 2 (8q22-23).
- cases without cytogenetic analysis: HMGA2 exon 2 or 3 is fused to RAD51L1 exon 7 (14q23.3-24).
- cases without cytogenetic analysis: HMGA2 isoforms due to aberrant alternative splicing.
- case without cytogenetic analysis: HMGA2 exon 2 is fused to the 3' portion of the HEI10 gene, located at 14q11.

**del(7)(q22-32) subgroup.**

It is found in approximately 17% of the karyotypically abnormal cases. It may be observed as the sole cytogenetic abnormality, or together with other changes. It is often associated with t(12;14) or alterations of the chromosome segment 12q14-15. The del(7q) clone is almost invariably found together with a normal clone.

A few cases with translocations involving 7q22 have been described. Myoma cells with del(7q) are not responsive to the immortalization by the 'early region' SV40 virus, unless they also contain 12q14-15 abnormalities. Myoma with del(7q) tend to be smaller than those showing 12q14-15 abnormalities.

**del(7)(q22-32) subgroup - molecular findings:** Conflicting minimal deletion regions have been proposed by multiple loss-of-heterozygosity (LOH) analyses using polymorphic microsatellite markers. The resultant tumor suppressor candidate genes, including CUTF1, ORL5L, PAI1, PCOLCE and LHFPL3, were not consistently altered in expression. Most recently, a study using 7q tiling path CGH microarrays confined the minimal deletion region to 2.79 Mb at 7q22 and also proposed a second region of loss at 7q34. However, no pathogenic coding variation was detected in the genes encompassed by the proposed region. At the present time the tumor-suppressor gene(s) responsible for del(7q) fibroid growth has not been identified despite much effort. This raises the possibility that a mechanism other than loss of tumor-suppressor gene function could be responsible for development of del(7q) fibroid tumors.

**6p21 rearrangement subgroup.**

Aberrations of the 6p21, including deletions, translocations, and inversions are found in less than 10% of the abnormal cases. 6p21 rearrangements may be observed as the sole cytogenetic abnormality, or together with other clonal changes. Simple and complex rearrangements of 6p21 have been observed. Complex rearrangements are sometimes definable only by FISH analysis. The most frequent translocation partners are chromosomes 1, 2, 4, 10 and 14 with rearrangements including t(1;6)(q23;p21), t(6;14)(p21;q24), and t(6;10)(q21;q22).

**6p21 rearrangement subgroup - molecular findings:** HMGA1 (formerly HMG1Y) (6p21.3) is the pathogenic sequence. No hybrid gene has been described yet. A genomic PAC clone containing the gene spans the 6p21.3 breakpoint. The breakpoint seems to be extragenic, located within an 80 kb region 3' of HMGA1.

One case of aberrant transcript with truncation of 1295 bp from the 3' UTR has been described.

**del(1)(p11p36) subgroup:**

This subgroup is characterized by an almost complete loss of the short arm of chromosome 1. Rearrangements are often observed with additional cytogenetic abnormalities such as the loss of chromosomes 19 and/or 22.

**del(1p) subgroup - molecular findings:** Transcriptional profiles with loss of 1p in UL resemble those of leiomyosarcoma suggesting a similar pathway for tumorigenesis. LOH analysis of polymorphic microsatellites confirmed deletion of the 1p region.

- **del(1)(p11p36) subgroup:**
  - t(1;6)(q23;p21)
  - t(6;14)(p21;q24)
  - t(6;10)(q21;q22)

- **6p21 rearrangement subgroup - molecular findings:**
  - HMGA1 (formerly HMG1Y) (6p21.3) is the pathogenic sequence. No hybrid gene has been described yet.
  - A genomic PAC clone containing the gene spans the 6p21.3 breakpoint. The breakpoint seems to be extragenic, located within an 80 kb region 3' of HMGA1.
  - One case of aberrant transcript with truncation of 1295 bp from the 3' UTR has been described.

**del(1)(p11p36) subgroup:**

This subgroup is characterized by an almost complete loss of the short arm of chromosome 1. Rearrangements are often observed with additional cytogenetic abnormalities such as the loss of chromosomes 19 and/or 22.

**del(1p) subgroup - molecular findings:**

Transcriptional profiles with loss of 1p in UL resemble those of leiomyosarcoma suggesting a similar pathway for tumorigenesis. LOH analysis of polymorphic microsatellites confirmed deletion of the 1p region.
Genes involved and Proteins

Note: Elevated levels of HMGAl expression have been observed in tumor cells and during embryonic tissue development suggesting that HMGAl proteins influence cell growth. Dysregulation of HMGAl (12q15) and HMGAl (6p21.3) genes have been observed in uterine leiomyomas. Mechanisms leading to dysregulation include fusion transcript formation, HMGAl truncation, and disruption of HMGAl regulatory sequences.

It has been suggested that the expression of HMGAl and HMGAl is controlled by regulatory elements within their 3'UTR: luciferase assays with HMGAl 3'UTRs of different length show an increase in luciferase activity by truncation of the 3'UTR. Of interest, HMGAl and HMGAl have been shown to contain multiple sites in their 3'UTRs predicted to be targets of micro RNAs, which likely play an important role in their regulation.

UL are also associated with insufficiency of FH (fumarate hydratase). FH encodes fumarase, involved in the key metabolic pathway of the Krebs cycle and may play a role in tumor development as a tumor suppressor gene. Structural rearrangements of 1q42,1 leading to missense mutations and various deletions (i.e., protein-truncating, large germline and in-frame) of FH can lead to haploinsufficiency and subsequent absent expression if the other FH allele is mutated.

References


Ingraham SE, Lynch RA, Kathiresan S, Buckler AJ, Menon AG, hrREC2, a RAD51-like gene, is disrupted by t(12;14) (q51;q24.1) in a uterine leiomyoma. Cancer Genet Cytogenet 1999;115:56-61.


Bormann L, Wilkening S, Bullerdiek J. The expression of HMG1 genes is regulated by their 3'UTR. Oncogene 2001;20:4537-4541.


Bormann L, Wilkening S, Bullerdiek J. The expression of HMG1 genes is regulated by their 3'UTR. Oncogene 2001;20(33):4537-4541.


This article should be referenced as such: